Optimal exercise modalities and doses for blood pressure management in adults with prehypertension and hypertension: A systematic review and Bayesian network meta-analysis.

MaturitasOct 16, 2026 (epub)

Yuan Yuan, Bopeng Qiu, Yumi Park et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and Bayesian network meta-analysis compared structured exercise modalities and estimated doses for blood pressure reduction in adults with prehypertension or stage 1 or 2 hypertension. It included 284 randomised controlled trials with 18,750 participants (mean age 56.8 years). Aquatic exercise had the largest estimated systolic reduction (mean difference −10.28 mmHg; 95% credible interval −13.05 to −7.49), while mind-body exercise had the largest estimated diastolic reduction (−4.69 mmHg; 95% credible interval −6.45 to −2.92). Dose-response models also identified modality-specific doses associated with maximal modeled benefit.

Key findings

  • Aquatic exercise ranked highest for systolic blood pressure reduction: mean difference −10.28 mmHg (95% credible interval −13.05 to −7.49).
  • Mind-body exercise had the largest estimated diastolic reduction: mean difference −4.69 mmHg (95% credible interval −6.45 to −2.92).
  • For isometric training, 750 metabolic equivalent task minutes per week was associated with maximal modeled systolic benefit: −13.52 mmHg (95% credible interval −23.22 to −3.86).
  • For aerobic exercise, 3600 metabolic equivalent task minutes per week was associated with maximal modeled diastolic benefit: −7.11 mmHg (95% credible interval −11.89 to −2.18).

Why it matters

The analysis suggests that blood pressure responses may differ by exercise modality and that estimated dose-response patterns are not uniform across modalities or systolic and diastolic outcomes. This can help frame exercise as a potentially tailored component of blood pressure management, while the comparative estimates and modeled doses should be interpreted in light of the underlying trial evidence.

What to keep in mind

The reported dose-response values are modeled estimates from a network meta-analysis, not direct evidence that these doses are optimal for every patient or hypertension phenotype.

Source

Published in Maturitas. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.